BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 12537005)

  • 1. Landmarks: examining the foundation for GP IIb/IIIa inhibitors in PCI.
    J Invasive Cardiol; 2002 Dec; 14(12):776-9. PubMed ID: 12537005
    [No Abstract]   [Full Text] [Related]  

  • 2. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization.
    Lenzen MJ; Boersma E; Bertrand ME; Maier W; Moris C; Piscione F; Sechtem U; Stahle E; Widimsky P; de Jaegere P; Scholte op Reimer WJ; Mercado N; Wijns W;
    Eur Heart J; 2005 Jun; 26(12):1169-79. PubMed ID: 15802360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence.
    Singh S; Gopal AK; Bahl VK
    Indian Heart J; 2005; 57(3):201-9. PubMed ID: 16196176
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
    Sabatine MS; Hamdalla HN; Mehta SR; Fox KA; Topol EJ; Steinhubl SR; Cannon CP
    Am Heart J; 2008 May; 155(5):910-7. PubMed ID: 18440341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
    D'Agate DJ; Patel S; Coppola JT; Ambrose JA
    J Invasive Cardiol; 2004 Sep; 16(9):500-3. PubMed ID: 15353833
    [No Abstract]   [Full Text] [Related]  

  • 6. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
    Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
    Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):907-8. PubMed ID: 18498141
    [No Abstract]   [Full Text] [Related]  

  • 8. Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
    Montalescot G; Van de Werf F; Gulba DC; Avezum A; Brieger D; Kennelly BM; Mazurek T; Spencer F; White K; Gore JM;
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):360-7. PubMed ID: 14571488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
    Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
    J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Bolus-only" glycoprotein IIb/IIIa inhibitor use for elective percutaneous coronary intervention: maybe less is more?
    Fischell TA
    Am Heart J; 2006 Nov; 152(5):812-4. PubMed ID: 17070138
    [No Abstract]   [Full Text] [Related]  

  • 12. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
    Tricoci P; Peterson ED
    J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter regarding article by Hlatky et al, "medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease".
    Osman F; Qaisar S; Pitt M
    Circulation; 2005 Apr; 111(13):e176-7; author reply e176-7. PubMed ID: 15811864
    [No Abstract]   [Full Text] [Related]  

  • 14. Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit.
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):498-9. PubMed ID: 18819148
    [No Abstract]   [Full Text] [Related]  

  • 15. Angioplasty in the diabetic patient.
    Van Belle E; Chmaït A; Bauters C; Lablanche JM
    J Invasive Cardiol; 2004 Jan; 16(1):23-7. PubMed ID: 14699219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
    Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
    J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Percutaneous coronary intervention].
    Csapó K
    Orv Hetil; 2005 Mar; 146(13):587-93. PubMed ID: 15856622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous coronary intervention for left main coronary artery disease.
    Gauthier N; Le May MR
    Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):213-20. PubMed ID: 17338666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.